Amanote Research
Register
Sign In
Novel Antibody-Drug Conjugate With Anti-Cd26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis
Cancers
- Switzerland
doi 10.3390/cancers11081138
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
August 8, 2019
Authors
Unknown
Publisher
MDPI AG
Related search
A Novel Monoclonal Antibody to Secreted Frizzled-Related Protein 2 Inhibits Tumor Growth
Molecular Cancer Therapeutics
Cancer Research
Oncology
MORAb-202, an Antibody Drug Conjugate Utilizing Humanized Anti-Human FRa Farletuzumab and the Microtubule-Targeting Agent Eribulin, Has Potent Anti-Tumor Activity
Molecular Cancer Therapeutics
Cancer Research
Oncology
Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, Inhibits Osteoarthritis
Arthritis Research and Therapy
Rheumatology
Allergy
Immunology
CD26 Is a Potential Therapeutic Target by Humanized Monoclonal Antibody for the Treatment of Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Molecular Predictors of Response to a Humanized Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody in Breast and Colorectal Cancer
Molecular Cancer Therapeutics
Cancer Research
Oncology
Preclinical Antilymphoma Activity of a Humanized Anti-Cd40 Monoclonal Antibody, SGN-40
Cancer Research
Cancer Research
Oncology
Tumor Stroma–targeted Antibody-Drug Conjugate Triggers Localized Anticancer Drug Release
Journal of Clinical Investigation
Medicine
Anti-Il-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth
Molecular Cancer Research
Cancer Research
Oncology
Molecular Biology
Infliximab (Anti–Tumor Necrosis Factor Α Antibody)
Archives of Dermatology
